A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 215-219, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-828550
ABSTRACT
OBJECTIVE@#To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19).@*METHODS@#We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517).@*RESULTS@#One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, >0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (>0.05).@*CONCLUSIONS@#The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neumonía Viral
/
ARN Viral
/
Diagnóstico por Imagen
/
China
/
Proyectos Piloto
/
Resultado del Tratamiento
/
Infecciones por Coronavirus
/
Usos Terapéuticos
/
Quimioterapia
/
Pandemias
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio diagnóstico
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Chino
Revista:
Journal of Zhejiang University. Medical sciences
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS